Markets:

Overview

News

Currencies

International

Treasuries

Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

79.44 +13.40 (+20.29%)

Streaming Delayed Price Updated: 11:22 AM EDT, Mar 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Apogee Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >

Wondering what's happening in today's pre-market session? ↗

Today 9:30 EDT

Via Chartmill

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗

March 18, 2026

Spyre Therapeutics focuses on antibody therapies for inflammatory bowel disease, advancing a pipeline aimed at gastrointestinal health.

Via The Motley Fool

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗

March 18, 2026

This ophthalmic biopharma firm develops sustained drug delivery therapies for eye diseases, targeting both U.S. and global markets.

Via The Motley Fool

Topics Regulatory Compliance

Apogee Therapeutics (NASDAQ:APGE) Reports Q4 2025 Results, Highlights Cash Runway and Key 2026 Clinical Catalysts ↗

March 02, 2026

Via Chartmill

VR Adviser Adds Over 1 Million Savara Shares ↗

March 15, 2026

This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials.

Via The Motley Fool

Topics Regulatory Compliance

Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗

March 04, 2026

Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing.

Via The Motley Fool

Topics Regulatory Compliance

Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing ↗

March 04, 2026

Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market.

Via The Motley Fool

Topics Regulatory Compliance

Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million ↗

February 25, 2026

This biotech specializes in monoclonal antibody therapies for inflammatory and immunological diseases with significant unmet needs.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges ↗

February 25, 2026

RAPT Therapeutics develops oral therapies for oncology and inflammatory diseases, with lead candidates progressing in clinical trials.

Via The Motley Fool

Topics Regulatory Compliance

Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst ↗

February 25, 2026

This clinical-stage biotech develops therapies targeting hematologic disorders, with a pipeline centered on red blood cell biology.

Via The Motley Fool

Topics Regulatory Compliance

The Great Rotation: Small-Cap Stocks Slay the Giants as Market Breadth Hits Record Highs

February 24, 2026

NEW YORK — After years of living in the shadow of trillion-dollar tech titans, the "little guys" of the stock market are finally having their day in the sun. As of February 24, 2026, the financial...

Via MarketMinute

Topics Economy Initial Public Offering

Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗

February 22, 2026

Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions.

Via The Motley Fool

Topics Regulatory Compliance

Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗

February 22, 2026

Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials.

Via The Motley Fool

Topics Regulatory Compliance

$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗

February 22, 2026

Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress ↗

February 14, 2026

Praxis Precision Medicines develops therapies for central nervous system disorders, with candidates targeting depression and epilepsy.

Via The Motley Fool

Topics Regulatory Compliance

Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million ↗

February 14, 2026

This clinical-stage biotech develops monoclonal antibody therapies targeting chronic inflammatory and immunological diseases.

Via The Motley Fool

Topics Regulatory Compliance

The Great Rotation: Russell 2000’s Historic 15-Day Streak Marks a Seismic Shift in Market Leadership

January 26, 2026

In a move that has rewritten the record books of Wall Street, the small-cap-heavy Russell 2000 index recently concluded a historic 15-session winning streak of daily outperformance against the S&P 500....

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

What Investors Should Know About a $1.5 Million Apogee Insider Sale Amid a 60% Stock Rally ↗

January 11, 2026

This clinical-stage biotech focused on long-acting antibody therapies reported a notable insider sale amid ongoing pipeline development.

Via The Motley Fool

Topics Regulatory Compliance

Apogee Therapeutics Chief Medical Officer Sells $817,500 Worth of Shares After Monster December Rally ↗

January 07, 2026

This clinical-stage biotech focused on immunology therapies reported a notable insider sale amid ongoing pipeline development.

Via The Motley Fool

Topics Regulatory Compliance

Why Apogee Therapeutics Stock Triumphed on Thursday ↗

October 09, 2025

The company aims to raise gross proceeds of roughly $300 million in a new capital-raising effort.

Via The Motley Fool

Delta Air Lines, Tilray Brands, UiPath, Akero Therapeutics, Apogee Therapeutics: Stocks Making The Biggest Moves Today ↗

October 09, 2025

Via Stocktwits

Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out ↗

October 09, 2025

The small biotech company is looking to take on Regeneron and Sanofi's blockbuster, Dupixent.

Via Investor's Business Daily

Helen of Troy, Ferrari, Apogee Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

October 09, 2025

Via Benzinga

Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket ↗

October 09, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 08, 2025

Via Benzinga

What's going on in today's after hours session ↗

October 08, 2025

Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.

Via Chartmill

Gold Falls 1%; ProKidney Shares Spike Higher ↗

July 08, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

July 07, 2025

Via Benzinga

Dow Dips 1%; Mustang Bio Shares Spike Higher ↗

July 07, 2025

Via Benzinga

Topics Stocks

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

July 07, 2025

Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.